Investing.com -- Daré Bioscience, Inc. (NASDAQ:DARE)股价上涨250%,此前该公司研发的无激素月度阴道内避孕产品Ovaprene的三期临床试验中期结果显示积极成果。 试验的独立数据安全监测委员会在审查安全数据后建议研究继续进行,无需修改。在中期分析时,约9%的接受治疗的女性出现怀孕,公司表示这与基于前期关键临床研究结果的预期一致。 中期分析未发现...
Source LinkInvesting.com -- Daré Bioscience, Inc. (NASDAQ:DARE)股价上涨250%,此前该公司研发的无激素月度阴道内避孕产品Ovaprene的三期临床试验中期结果显示积极成果。 试验的独立数据安全监测委员会在审查安全数据后建议研究继续进行,无需修改。在中期分析时,约9%的接受治疗的女性出现怀孕,公司表示这与基于前期关键临床研究结果的预期一致。 中期分析未发现...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.